简介:【 摘要】: 目的 观察分析 联合应用 双歧杆菌与 铋剂四联疗法治疗幽门螺杆菌( Hp) 感染的 临床效果 。方法 选择我院 2017 年 3 月 -2018 年 12 月收治的 124 例 消化性溃疡 Hp 感染患者 作 为 本次的 研究对象,随机 将其 分为 例数相同的两组:研究 组和对照组,每组患者 62 例。 对照组患者采用 四联疗法治疗 , 研究 组患者 在使用四联疗法基础上加用双歧杆菌三联活菌。比较两组 患者 的临床疗效以及治疗前后 胃液 pH 值、白细胞介素 -8 ( IL-8 )以及肿瘤坏死因子( TNF-α )等水平变化。 结果 研究组患者的临床总有效率为 93.55% ,明显高于对照组的 80.65% ,差异有统计学意义( P<0.05 )。两组患者治疗后胃液 pH 值、 IL-8 以及 TNF-α 等水平均明显低于对照组,差异有统计学意义( P<0.05 )。研究组治疗后胃液 pH 值、 IL-8 以及 TNF-α 水平降低较对照组更加显著,差异有统计学意义( P<0.05 )。 结论 联合应用 双歧杆菌三联活菌与 铋剂四联方案治疗消化性溃疡 HP感染患者可以取得满意 的临床效果, 患者的 胃液 pH 值 得到显著改善 , 机体 炎症反应水平 明显降低 ,值得 在临床上广泛的 推广 。
简介: [摘要 ] 目的 探讨美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的疗效及其对炎性因子的影响。 方法 选取 2018年 1月~ 2020年 1月我院收治的溃疡性结肠炎患者 80例,随机分为两组,每组各 40例,两组患者均予常规对症治疗,同时两组均予美沙拉嗪缓释颗粒,观察组同时加用双歧三联活菌胶囊,治疗后比较两组患者治疗后的临床疗效,以及两组患者治疗前后 TNF-α、 IL-10水平的变化情况及两组患者治疗前后的临床症状积分变化情况。结果 观察组治疗后的总有效率为 95.00%,显著高于对照组的总有效率 70.00%,两组疗效比较差异具有显著性( P<0.05)。治疗后,两组患者的炎性因子 TNF-α、 IL-10水平较治疗前显著降低( P<0.05)。且观察组患者治疗后的 TNF-α、 IL-10水平显著低于对照组( P<0.05)。观察组患者治疗后的临床症状积分为( 2.56±0.85)分,与治疗前及对照组比较,差异有统计学意义( P<0.05)。 结论 美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎疗效确切,且可以抑制炎症反应,值得临床推广和应用。 [关键词 ] 溃疡性结肠炎 ;美沙拉嗪 ;双歧三联活菌 ;炎性因子 [Abstract] Objective To investigate the efficacy of mesalazine combined with Bifid Triple Viable Bacteria in the treatment of ulcerative colitis and its influence on inflammatory factors. method Methods: 80 patients with ulcerative colitis in our hospital from January 2018 to January 2020 were selected and randomly divided into two groups, 40 cases in each group. Both groups were given conventional symptomatic treatment, while the two groups were given mesalazine sustained-release granules. The observation group was also given Bifid Triple Viable capsules. After treatment, the clinical efficacy of the two groups of patients after treatment, as well as TNF - α, IL-10 water before and after treatment, were compared between the two groups The changes of the two groups of patients before and after treatment of clinical symptoms integral changes. Results the total effective rate of the observation group was 95.00%, which was significantly higher than that of the control group (70.00%). There was a significant difference between the two groups (P < 0.05). After treatment, the levels of inflammatory factors TNF - α and IL-10 in the two groups were significantly lower than those before treatment (P < 0.05). The levels of TNF - α and IL-10 in the observation group were significantly lower than those in the control group (P < 0.05). The clinical symptom score of the observation group after treatment was (2.56 ± 0.85), and the difference was statistically significant (P < 0.05). Conclusion mesalazine combined with Bifid Triple Viable Bacteria is effective in the treatment of ulcerative colitis, and can inhibit inflammatory reaction, which is worthy of clinical promotion and application.